BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery

BioAge Labs, Inc. (NASDAQ:BIOA) is one of the 11 Best New Penny Stocks to Buy Right Now. On June 17, BioAge Labs, Inc. (NASDAQ:BIOA) announced a new initiative to profile and analyze samples from the HUNT Biobank in Norway.

The company will generate and analyze molecular profiles from more than 17,000 samples collected over decades of aging from more than 6,000 participants. BioAge Labs, Inc. (NASDAQ:BIOA) will use these samples to generate millions of molecular readouts.

By carefully analyzing this data along with the health records of the participants, BioAge Labs, Inc. (NASDAQ:BIOA) aims to expand the proprietary human aging data that supports the company’s drug-discovery platform. The company has exclusive rights to use this data for drug discovery.

This initiative builds on the company’s existing network of biobank partnerships. BioAge Labs, Inc. (NASDAQ:BIOA) expects this partnership to help accelerate its ability to find drug targets that maintain physiological resilience and help counter age-related disease.

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases by targeting the biology of human aging.

While we acknowledge the potential of BIOA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.